(Q42937306)

11 November 2017

Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases (English)

1 reference

11 November 2017

María Concepción López-Carrizosa

series ordinal

1

1 reference

PubMed ID

20709654

11 November 2017

Pilar María Samper-Ots

series ordinal

2

1 reference

PubMed ID

20709654

11 November 2017

Aurora Rodríguez Pérez

series ordinal

3

1 reference

11 November 2017

1 August 2010

1 reference

Clinical and Translational Oncology

11 November 2017

1 reference

11 November 2017

12

1 reference

11 November 2017

8

1 reference

11 November 2017

568-573

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-010-0555-z

11 November 2017

0 references

cites work

Use of markers of bone turnover for monitoring bone metastases and the response to therapy

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-010-0555-Z

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-010-0555-Z

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

12 December 2020

Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis

1 reference

12 December 2020

Markers of bone resorption in patients treated with pamidronate

1 reference

12 December 2020

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

1 reference

12 December 2020

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

12 December 2020

Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions

1 reference

12 December 2020

Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).

1 reference

12 December 2020

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

1 reference

12 December 2020

Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer

1 reference

12 December 2020

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

1 reference

12 December 2020

Clinical features of metastatic bone disease and risk of skeletal morbidity

1 reference

12 December 2020

Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC).

1 reference

12 December 2020

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

1 reference

12 December 2020

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

1 reference

12 December 2020

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity

1 reference

12 December 2020

Antitumor effects of bisphosphonates

1 reference

12 December 2020

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

12 December 2020

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs

1 reference

12 December 2020

Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer

1 reference

12 December 2020

Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma

1 reference

12 December 2020

Bone resorption predicts for skeletal complications in metastatic bone disease

1 reference

12 December 2020

Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.

1 reference

12 December 2020

10.1007/S12094-010-0555-Z

Identifiers

DOI

1 reference

11 November 2017

1 reference

PubMed ID

20709654